AstraZeneca closed its $140 million investment in Cellectis Monday, giving the Anglo-Swedish drugmaker a 44% stake in the French gene-editing company which leverages an allogeneic approach for CAR-T immunotherapies in oncology.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,